Investment Rating - The investment rating for the company is "Buy" [7] Core Views - The company has shown strong performance in overseas markets, with a revenue increase of 27.67% in 2024, while domestic revenue grew by 9.32% despite pricing pressures from procurement policies [2][3] - The company is expanding its high-end product offerings and increasing its market share in both domestic and international markets, with significant progress in the installation of high-end models [4] - Profit growth is lagging behind revenue growth due to fluctuations in gross margins influenced by procurement pressures [3] Financial Performance Summary - In 2024, the company achieved a total revenue of 45.35 billion yuan, a year-on-year increase of 15.41%, and a net profit of 18.28 billion yuan, up 10.57% [1] - The gross margin for 2024 was 72.07%, slightly down by 0.89 percentage points from the previous year, with a notable increase in the proportion of lower-margin equipment sales [2] - For Q1 2025, the company reported a revenue of 11.25 billion yuan, a 10.12% increase year-on-year, while net profit grew by 2.65% [1][3] Market Expansion and Product Development - The company has successfully increased its coverage in tier-three hospitals, reaching a coverage rate of 44.93% in the domestic market [4] - In 2024, the company installed 4,017 units in overseas markets, with high-end models accounting for 67.16% of installations [4] - The company is actively establishing subsidiaries in key international markets, including Indonesia, Malaysia, and Thailand, to enhance its global presence [4] Future Projections - Revenue projections for 2025-2027 are estimated at 51.58 billion yuan, 60.07 billion yuan, and 70.75 billion yuan, respectively, with expected growth rates of 13.7%, 16.5%, and 17.8% [4] - Net profit forecasts for the same period are 20.63 billion yuan, 24.27 billion yuan, and 28.74 billion yuan, with growth rates of 12.8%, 17.6%, and 18.4% [4]

Investment Rating - The investment rating for the company is "Buy" [6] Core Views - The company's performance in 2024 faced temporary pressure due to domestic industry restructuring and equipment update cycles, while overseas markets experienced rapid growth. The first quarter of 2025 showed positive year-on-year growth in both revenue and profit, indicating a gradual release of equipment update demand. The company achieved breakthroughs in high-end markets and penetration in emerging regions, enhancing its global product layout [2][3] Financial Performance Summary - In 2024, the company reported revenue of 10.3 billion yuan, a year-on-year decline of 9.73%, and a net profit of 1.262 billion yuan, down 36.09%. The first quarter of 2025 saw revenue of 2.478 billion yuan, an increase of 5.42%, and a net profit of 370 million yuan, up 1.87% [1][5] - The service business showed strong performance in 2024, with revenue of 1.356 billion yuan, a year-on-year increase of 26.80%, and a gross margin of 63.43%. In contrast, the equipment business faced challenges, with revenue of 8.445 billion yuan, a decline of 14.93% [2] - The company’s overseas revenue reached 2.220 billion yuan in 2024, a year-on-year increase of 33.81%, while domestic revenue was 7.664 billion yuan, down 19.43% [3] Product and Market Development - The company has launched over 140 innovative products by the end of 2024, with significant certifications including 46 CE MDR and 49 FDA approvals. Notable products include advanced MRI and CT systems, enhancing the product portfolio [4] - The company has expanded its overseas business to over 85 countries and regions, achieving significant market penetration in North America and Europe, and making strides in emerging markets such as India, Turkey, Mexico, and Brazil [3] Future Projections - Revenue projections for 2025-2027 are estimated at 12.354 billion yuan, 15.130 billion yuan, and 18.326 billion yuan, representing year-on-year growth rates of 19.9%, 22.5%, and 21.1% respectively. Net profit projections for the same period are 1.803 billion yuan, 2.245 billion yuan, and 2.746 billion yuan, with growth rates of 42.8%, 24.6%, and 22.3% respectively [4][5]

迈瑞医疗（300760.SZ） 政策扰动下 25Q1 短期承压，招标恢复趋势下看好业绩逐季改善 迈瑞医疗发布 2024 年度报告。2024 年公司实现营业收入 367.26 亿元，同比增长 5.14%；归母净利润 116.68 亿元，同比增长 0.74%；扣非后归母净利润 114.42 亿元， 同比增长 0.07%。分季度看，2024Q4 实现营业收入 72.41 亿元，同比下滑 5.08%；归 母净利润 10.31 亿元，同比下滑 40.99%；扣非后归母净利润 10.05 亿元，同比下滑 42.49%。 迈瑞医疗发布 2025 年度一季报。2025Q1 公司实现营业收入 82.37 亿元，同比下滑 12.12%；归母净利润 26.29 亿元，同比下滑 16.81%；扣非后归母净利润 25.31 亿元， 同比下滑 16.68%。 观点：2024 年体外诊断业务稳健增长，高端超声 A20 放量驱动医学影像板块增长， 种子业务蓄势待发，多产品线各放异彩。2025Q1 业绩阶段性承压，主要系国内政策 扰动及海外同期高基数影响，预计 2025Q3 迎来重大拐点。海外收入占比持续提升， 高端客户群不断突破，奠定长远增 ...

一、当周（4.28-4.30）回顾与周专题： 当周（4.28-4.30）申万医药指数环比+0.49%，跑赢创业板指数，跑赢沪深 300 指数。 本周周报，我们对医药年报&一季报进行了总结。 证券研究报告 | 行业周报 gszqdatemark 2025 05 05 年 月 日 医药生物 【周专题&周观点】【总第 395 期】医药年报&一季报总结 二、近期复盘： 1、当周表现：本周市场（交易三天）整体震荡下行，A 股医药指数强于市场，活跃度 很好，表现比较好的包括：部分创新药、部分减肥条线、一季报超预期、药店、外骨骼 机器人等。港股医药在周一受到冲击下跌后，后续持续走强，重心还是在创新药，中小 市值表现更好一些。 2、原因分析：虽然本周只交易了 3 天，但医药的反应是超大家预期的，体现在两个方 面：第一是创新药，上周末康方出数据之后，市场整体反应给我们的感觉是市场对于创 新药的认知和交易更为成熟，信心和热度更为超预期（错杀的快速修复并创新高），此 外新诺威和科伦的走势，也是强化了市场对于创新药的信心，第二是一季报低于预期后 的反应，一季报整体是不好的，但有一些公司走出了强势利空出尽的感觉，比如华大智 造、科伦药 ...

证券研究报告 | 行业点评 gszqdatemark 2025 05 04 年 月 日 房地产 重点标的 | 股票 | 股票 | 投资 | | EPS（元） | | | | | PE | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 代码 | 名称 | 评级 | 2024A | 2025E | 2026E | 2027E | 2024A | 2025E | 2026E | 2027E | | 001979.SZ | 招商蛇口 | 买入 | 0.45 | 0.49 | 0.55 | 0.62 | 21.50 | 18.61 | 16.55 | 14.76 | | 002244.SZ | 滨江集团 | 买入 | 0.82 | 0.90 | 0.95 | 0.99 | 12.20 | 11.57 | 10.92 | 10.50 | | 600048.SH | 保利发展 | 买入 | 0.42 | 0.43 | 0.47 | 0.53 | 19.90 | 19.60 | 17.75 | 15.92 | | 600325. ...

证券研究报告 | 行业周报 gszqdatemark 2025 05 05 年 月 日 医药生物 【周专题&周观点】【总第 395 期】医药年报&一季报总结 一、当周（4.28-4.30）回顾与周专题： 当周（4.28-4.30）申万医药指数环比+0.49%，跑赢创业板指数，跑赢沪深 300 指数。 本周周报，我们对医药年报&一季报进行了总结。 二、近期复盘： 1、当周表现：本周市场（交易三天）整体震荡下行，A 股医药指数强于市场，活跃度 很好，表现比较好的包括：部分创新药、部分减肥条线、一季报超预期、药店、外骨骼 机器人等。港股医药在周一受到冲击下跌后，后续持续走强，重心还是在创新药，中小 市值表现更好一些。 2、原因分析：虽然本周只交易了 3 天，但医药的反应是超大家预期的，体现在两个方 面：第一是创新药，上周末康方出数据之后，市场整体反应给我们的感觉是市场对于创 新药的认知和交易更为成熟，信心和热度更为超预期（错杀的快速修复并创新高），此 外新诺威和科伦的走势，也是强化了市场对于创新药的信心，第二是一季报低于预期后 的反应，一季报整体是不好的，但有一些公司走出了强势利空出尽的感觉，比如华大智 造、科伦药 ...

Investment Rating - The report maintains a "Buy" rating for the company [7] Core Views - The company is transitioning its growth momentum towards the domestic market, with a notable decline in profitability due to subsidiary losses and convertible bond expenses [1] - The VIP board segment shows resilience with a revenue increase of 11.39% year-on-year, despite a slight decrease in average selling price [2] - The company is actively engaging in cash dividends and share buybacks to enhance shareholder returns [4] - The company is positioned as a leader in the vacuum insulation panel industry, with significant growth potential in both domestic and international markets [5] Financial Performance Summary - In 2024, the company reported revenue of 934 million yuan, an increase of 11.16% year-on-year, but a net profit decline of 27.27% to 77.16 million yuan [1] - The gross margin for 2024 was 29.12%, down 3.91 percentage points, attributed to a decrease in terminal average prices and rising raw material costs [3] - The operating cash flow for 2024 was 65.65 million yuan, a decrease of 12.67% year-on-year, primarily due to increased costs outpacing revenue growth [4] - The company forecasts net profits of 100 million yuan, 140 million yuan, and 170 million yuan for 2025, 2026, and 2027 respectively, with corresponding P/E ratios of 25X, 17X, and 14X [5] Market Dynamics - The company’s domestic sales ratio increased to 56.91% in 2024, up 11.98 percentage points year-on-year, driven by domestic replacement policies [2] - The overall industry remains in a high demand phase, with the VIP board segment benefiting from both domestic and international market dynamics [2]

证券研究报告 | 年报点评报告 gszqdatemark 2025 05 04 年 月 日 鱼跃医疗（002223.SZ） 主业回归常态化轨道，海外市场高速增长 鱼跃医疗发布 2024 年度报告。2024 年公司实现营业收入 75.66 亿元，同比下滑 5.09%；归母净利润 18.06 亿元，同比下滑 24.63%；扣非后归母净利润 13.93 亿 元，同比下滑 24.12%。分季度看，2024Q4 实现营业收入 15.38 亿元，同比增长 17.51%；归母净利润 2.74 亿元，同比增长 33.60%；扣非后归母净利润 1.19 亿 元，同比下滑 28.01%。 鱼跃医疗发布 2025 年度一季报。2025Q1 公司实现营业收入 24.36 亿元，同比增 长 9.17%；归母净利润 6.25 亿元，同比下滑 5.26%；扣非后归母净利润 5.13 亿 元，同比下滑 6.91%。 观点：2024 年业务逐步回归常态化，收入端短期承压主要系同期高基数影响，利 润端表现不及收入端，主要系毛利率波动+期间费用率抬升，及去年同期资产处置 收益较高影响。营销投入持续加大，为新产品开拓市场提供支撑。海外属地化建 设持 ...

证券研究报告 | 行业周报 gszqdatemark 2025 05 04 年 月 日 农林牧渔 2025Q1 农业板块业绩简述 本周热点：2025Q1 农业板块业绩简述。2025 年一季度，SW 农林牧渔板 块实现合计利润 135.1 亿元，同比增长 1049%，其中，养殖业、饲料、农 产品加工板块贡献较高，分别占利润的 59%、16%、15%。1）养殖业： 实现利润 80 亿元，同比增长 254%，其中生猪养殖 76.15 亿元，同比增 长 242%；肉鸡养殖 3.8 亿元，同比增长 155%。从价格端看，2025 年一 季度，搜猪网肉猪均价 15.2 元/kg，同比增长 4%；博亚和讯白羽鸡产品 均价 9.1 元/kg，同比下跌 5.9%；新牧网黄羽中速鸡均价 11.5 元/kg，同 比下跌 8%，总体看，除猪价外，畜禽产品价格表现相对低迷，但饲料端 价格亦疲软，据发改委，生猪饲料、肉鸡饲料分别 2.7 元/kg、3.2 元/kg， 同比分别下降 16%、10%，因此养殖板块利润增长更多来自于原料价格及 养殖成本下降贡献。2）饲料、动保：分别实现利润 21.43 亿元、5.12 亿 元，同比分别增长 6 ...

证券研究报告 | 行业周报 gszqdatemark 2025 05 04 年 月 日 有色金属 美国关税态度趋缓，外盘金属价格偏强震荡 黄金：一季度黄金 ETF 流入推高全球总需求，中期仍具备上涨动能。短期特朗普释放缓和 关税信号缓解避险情绪，美国近期经济硬数据整体表现韧性，一季度 GDP 因进口大增转负， 但并未大幅低于市场预期，4 月非农就业人口 17.7 万人（前值 18.5，预期值 13），失业率也 符合预期，一方面降低了经济衰退的担忧，另一方面也推迟了美联储的降息时间。供需方面， 根据世界黄金协会，2025Q1，全球黄金投资总需求量为 552 吨，同比暴增 170%。其中，金 条金币总需求为 325 吨，同比增长 3%；黄金 ETF 净流入 226 吨，成为推高一季度投资总需 求的最主要因素。一季度，全球央行净购金 244 吨，同比减少 21%，但与过去 3 年全球央 行持续大规模购金的季度平均水平持平，表明购金态势依旧强劲。建议关注：紫金矿业、山 东黄金、赤峰黄金、银泰黄金、招金矿业等。 工业金属：（1）铜：库存继续回落，短期关税缓和铜价反弹。①宏观方面：特朗普关税态 度缓和后，市场风险偏好短期 ...